X4 Pharmaceuticals (XFOR) Cash from Investing Activities (2017 - 2025)

X4 Pharmaceuticals posted quarterly Cash from Investing Activities of $16.8 million for Q4 2025, up 295.44% year-on-year from $4.3 million in Q4 2024, and up 158.77% on a QoQ basis from -$28.7 million in Q3 2025.

X4 Pharmaceuticals (XFOR) has 9 years of Cash from Investing Activities data on file, last reported at $16.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 295.44% year-over-year to $16.8 million; the trailing twelve-month figure through Dec 2025 stood at $8.2 million (down 87.83% YoY), and the FY2025 full-year result was $8.2 million, down 87.83% from the prior year.
  • Cash from Investing Activities for Q4 2025 stood at $16.8 million, up from -$28.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $96.9 million in Q2 2024 and bottomed at -$28.7 million in Q3 2025.
  • The 5-year median for Cash from Investing Activities is -$62000.0 (2021), against an average of $3.0 million.
  • Peak annual rise in Cash from Investing Activities reached 2083.25% in 2024, while the deepest fall reached 59033.33% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$13000.0 in 2021, then sank by 161.54% to -$34000.0 in 2022, then tumbled by 14114.71% to -$4.8 million in 2023, then slumped by 78.38% to -$8.6 million in 2024, then jumped by 295.44% to $16.8 million in 2025.
  • The last three Cash from Investing Activities figures came in at $16.8 million (Q4 2025), -$28.7 million (Q3 2025), and $23.1 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -2.89 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -431.90 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -428.90 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -25.54 Mn
10 X4 Pharmaceuticals 182.28 Mn 182.28 Mn 2.20 Mn 16.85 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 16.85 Mn
Dec 31, 2025 16.85 Mn
Sep 30, 2025 -28.67 Mn
Sep 30, 2025 -28.67 Mn
Jun 30, 2025 23.11 Mn
Jun 30, 2025 23.11 Mn
Mar 31, 2025 -3.14 Mn
Mar 31, 2025 -3.14 Mn
Dec 31, 2024 -8.62 Mn
Dec 31, 2024 -8.62 Mn
Sep 30, 2024 -15.93 Mn
Sep 30, 2024 -15.93 Mn
Jun 30, 2024 96.86 Mn
Jun 30, 2024 96.86 Mn
Mar 31, 2024 -5.32 Mn
Mar 31, 2024 -5.32 Mn
Dec 31, 2023 -4.83 Mn
Dec 31, 2023 -4.83 Mn
Sep 30, 2023 -5.16 Mn
Sep 30, 2023 -5.16 Mn
Jun 30, 2023 -4.88 Mn
Jun 30, 2023 -4.88 Mn
Mar 31, 2023 -9,000.00
Mar 31, 2023 -9,000.00
Dec 31, 2022 -34,000.00
Dec 31, 2022 -34,000.00
Sep 30, 2022 -9,000.00
Sep 30, 2022 -9,000.00
Jun 30, 2022 -38,000.00
Jun 30, 2022 -38,000.00
Mar 31, 2022 -22,000.00
Mar 31, 2022 -22,000.00
Dec 31, 2021 -13,000.00
Dec 31, 2021 -13,000.00
Sep 30, 2021 -20,000.00
Sep 30, 2021 -20,000.00
Jun 30, 2021 -86,000.00
Jun 30, 2021 -86,000.00
Mar 31, 2021 -496,000.00
Mar 31, 2021 -496,000.00
Dec 31, 2020 -302,000.00
Dec 31, 2020 -302,000.00
Sep 30, 2020 -496,000.00
Sep 30, 2020 -496,000.00
Jun 30, 2020 -9,000.00
Jun 30, 2020 -9,000.00
Mar 31, 2020 -555,000.00
Mar 31, 2020 -555,000.00
Dec 31, 2019 21,000.00
Dec 31, 2019 21,000.00
Sep 30, 2019 815,000.00
Sep 30, 2019 815,000.00
Jun 30, 2019 -10,000.00
Jun 30, 2019 -10,000.00
Mar 31, 2019 26.41 Mn
Mar 31, 2019 26.41 Mn
Sep 30, 2018 27,000.00
Sep 30, 2018 27,000.00
Dec 31, 2017 -319,000.00
Dec 31, 2017 -319,000.00
Sep 30, 2017 -18,000.00
Sep 30, 2017 -18,000.00
Jun 30, 2017 -24,000.00
Jun 30, 2017 -24,000.00
Mar 31, 2017 -17,000.00
Mar 31, 2017 -17,000.00